PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Beijing Med-Pharm Corporation (NASDAQ:BJGP) (“Beijing Med-Pharm” or the “Company”), one of China’s leading pharmaceutical companies, and Shanghai Novartis Trading Limited, a wholly owned subsidiary of Novartis AG (NYSE: NVS), one of the top five pharmaceutical companies in the world, today announced an exclusive agreement to register, market and distribute Enablex® (Darifenacin) in the People’s Republic of China.
